BlackRock Portfolio Management LLC filed an amended Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 3,491,612 shares of RxSight, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock Portfolio Management LLC reported beneficial ownership of 3,491,612 shares of RxSight, Inc. common stock.
  • Percent of class: The reported position represents 8.4% of the outstanding common shares, according to the filing.
  • Sole voting power: The filing discloses sole voting power over 3,082,879 shares.
  • Sole dispositive power: Sole power to dispose of or direct the disposition of 3,491,612 shares is reported.
  • Shared voting and dispositive power: Both shared voting power and shared dispositive power are reported as 0.
  • Triggering date: The event requiring this filing occurred on September 30, 2026.

BlackRock Portfolio Management LLC's Position in RxSight Common Stock

According to the amended Schedule 13G (Amendment No. 1), BlackRock Portfolio Management LLC, a Delaware-organized entity headquartered at 50 Hudson Yards, New York, NY 10001, disclosed beneficial ownership of 3,491,612 shares of RxSight, Inc. (NASDAQ:RXST) common stock (CUSIP 78349D107). The filing was signed by Spencer Fleming, Managing Director, on October 27, 2026, and reflects holdings as of the event date of September 30, 2026.

The filing states that this Schedule 13G "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates," and that it "does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units." The filing classifies BlackRock Portfolio Management LLC as a holding company (type "HC") for purposes of this report.

Regarding the interests of underlying beneficiaries, the filing discloses that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of RxSight, Inc." and that "no one person's interest in the common stock of RxSight, Inc. is more than five percent of the total outstanding common shares." The filer certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

What Was Disclosed

BlackRock Portfolio Management LLC filed an amended Schedule 13G reporting beneficial ownership of 3,491,612 shares, or 8.4%, of RxSight, Inc. common stock as of September 30, 2026, with sole voting power over 3,082,879 shares and sole dispositive power over the full 3,491,612 shares.